Millennium Adopts Bioscale's ViBE Platform as Part of its Drug Development Workflow
January 14, 2011
Millennium Adopts Bioscale's ViBE Platform as Part of its Drug Development Workflow
The drugmaker, which purchased a system in August after several months of trying out a beta version, is using it to measure pharmacodynamic biomarkers, and has found it cuts run times for such assays from a week down to as little as a day.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- BioScale Secures $25M for Commercialization of Acoustic-Based Protein Analytics System
June 18, 2010 / ProteoMonitor - IFOM Researchers Analyze Effect of EGF-Activation on Protein Ubiquitination
February 4, 2011 / ProteoMonitor - Proteomics Firms Net More than $8.75M in IRS Funds; Bulk of Awards Aimed at Diagnostics Work
November 5, 2010 / ProteoMonitor - Movers & Shakers
October 15, 2010 / ProteoMonitor - BioScale Presents Data Showing Application of AMMP Technology to Cytokine Assay Development
January 18, 2013 / ProteoMonitor